The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Pre-clinical studies in CTCL
Jan P. Nicolay
• 15 Oct 2021
Jan P. Nicolay, MD, Ruprecht Karls University of Heidelberg, Mannheim, Germany, comments on recent pre-clinical studies in the field of cutaneous T-cell lymphoma (CTCL) which have identified novel treatment targets including CXCL-CXCR interactions and CD30. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
